top of page
Precision Therapy for Diabetes
Solutions and Goals
1
Cell-surface membrane proteins provide entry points for therapeutic interventions.
ZnT8, a zinc-specific transporter, is a dynamic cell-surface marker for beta cells.
​
ZnT8 in the human body is exclusively localized in the pancreatic islet.
​
We have developed a ZnT8-targted drug delivery platform for pancreatic islets.
​
We have established preclinical efficacy and safety of an islet-targeted immunotherapy for type-1 diabetes.
​
We aim to develop a suite of diabetes-modifying therapeutics that can be administered monthly at home, replacing frequent insulin injections and blood glucose monitoring for patients with insulin-dependent diabetes.
​
bottom of page